|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 60.3 TWD | +2.20% |
|
+10.24% | +19.88% |
| Mar. 11 | TSH Biopharm Corporation Limited Announces Directorate Changes on April 1, 2024 | CI |
| Mar. 11 | TSH Biopharm Corporation Limited Appoints Jung-Liang Kao as CFO on April 1, 2024 | CI |
TSH Biopharm Corporation Limited reported earnings results for the full year ended December 31, 2022. For the full year, the company reported sales was TWD 464.38 million compared to TWD 413.48 million a year ago. Net income was TWD 61.89 million compared to TWD 47.11 million a year ago.
Basic earnings per share from continuing operations was TWD 1.61 compared to TWD 1.23 a year ago. Diluted earnings per share from continuing operations was TWD 1.61 compared to TWD 1.23 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| +19.88% | 70.98M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
TSH BIOPHARM CORPORATION LIMITED 
